Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zeaxanthin - Cardax Pharmaceuticals

Next Previous
Drug Profile

Zeaxanthin - Cardax Pharmaceuticals

Alternative Names: CDX-301-Cardex Pharmaceuticals; CDX301

Latest Information Update: 10 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardax Pharmaceuticals
  • Class Anti-inflammatories; Eye disorder therapies; Small molecules; Xanthophylls
  • Mechanism of Action Antioxidants; Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Macular degeneration
  • Discontinued Stargardt disease

Most Recent Events

  • 01 Oct 2021 Zeaxanthin - Cardax Pharmaceuticals is available for licensing as of 01 Oct 2021. https://cardaxpharma.com/cdx-301/ (Cardax Pharmaceuticals pipeline, October 2021)
  • 01 Oct 2021 Preclinical trials in Macular degeneration in USA (unspecified route) (Cardax Pharmaceuticals pipeline, October 2021)
  • 31 Dec 2020 Discontinued - Preclinical for Stargardt disease in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top